个人简介

方沈应，南方科技大学公共卫生及应急管理学院教授、研究员、博士生导师。获美国德克萨斯大学生物统计学博士，曾任德克萨斯大学MD安德森癌症研究中心肿瘤外科系助理教授、副教授，武汉科技大学特聘教授，广州医科大学“南山学者”特聘教授。任PLOS ONE、Advances in Public Health 及 Frontiers in Oncology杂志编辑，担任American Journal of Human Genetics、Journal of National Cancer Institute、PLOS Genetics、International Journal of Cancer、Carcinogenesis以及Scientific Reports等13本英文杂志评委，并参与National Science Center (NCN panel NZ7， Poland)和中国国家自然基金委基金评审；为美国癌症协会、遗传学会和统计学会会员。主要运用流行病学与生物统计学方法研究环境因素、遗传因素与恶性肿瘤或慢性病的发生、发展及预后的关系。参与收集了北美最大的黑色素瘤病例对照研究人群并创建了北美黑色素瘤风险预测模型。目前主要运用遗传学、生物信息学及机器学习法，深度挖掘研究病人个体基因组学特征、疾病临床表现信息，包括影像学资料和病理组织学染色图片等医疗大数据，为肿瘤的早期诊断、个体化治疗、疾病复发及生存预后提供相应依据。研究成果发表于J Clin Oncol.（第一作者3篇， 共同作者5篇）, J Invest Dermatol.（通讯作者4篇）, Nature Genetics（4篇），Int J Cancer（第一作者3篇， 共同作者6篇），The Lancet Oncology（1篇），Cancer（6篇）等国际著名刊物。近期的研究成果被Cancer network、NEJM等专业媒体报道, 于2011美国遗传学年会及2020年全球华人统计学年会获大会报告, 在SCI等刊物发表英文论文70余篇。

研究方向

1. 人群流行病学研究：依据大湾区人群样本，开展人群流行病学观察研究，调查研究环境因素与遗传因素在慢性病、肿瘤或新发传染病发生、发展中的作用，为采取干预措施以降低疾病的发病风险提供依据。

2. 健康医疗大数据应用：（1）依托附属医院及合作医疗单位，收集肿瘤病人的血液及组织样本，建立患者医疗数据库；（2）结合TCGA肿瘤数据库及本地医院人群标本库，同MD安德森研究中心、Baylor医学院以及St Jude儿童医院等开展多中心合作，整合分析多组学—基因组、转录组、表观基因组、蛋白组及代谢组学等多层组学数据，同时纳入人口统计学或临床表型变量，应用统计学与人工智能新理论—神经网络模型（CNN）、变分自编码器模型(VAE)以及条件生成对抗网络模型（CGAN），对高维数据降维并压缩提取特征变量，以预测疾病的发生、发展及预后，并为精准治疗提供依据；（3）机器学习及数据科学在医疗影像资料—数字化组织病理学图像、CT、MRI等中的应用，包括质量控制、聚类分割、标识、特征提取及结果预测，为提高疾病的诊断、危险度分层及指导精准治疗和预后评估提供依据，并且可藉此发展出新的治疗手段与科技转化平台；发展机器学习新模型-Transformer，并应用于图像处理分析以及识别肿瘤驱动基因；（4）协同附属医院，开展临床流行病学研究，科学实施临床实验设计与诊断性试验评价,以及针对治疗方案开展卫生经济学评估与决策分析，为政策制订者提供依据。

3. 生物信息学研究：评估肿瘤微环境中的免疫细胞、肿瘤细胞及间质细胞的构成演变在肿瘤转移、预后与治疗中的作用。

4. 疾病病因学推论：孟德尔随机化研究设计及病因推论；运用加性噪声模型进行因果关联分析。

5. 统计学模型在遗传流行病学中的应用：多因子风险评估、基因-基因，基因-环境交互作用。

教育经历

2004/08-2008/12，美国德克萨斯大学生物统计学，博士

2003/01-2004/07，美国德克萨斯大学生物统计学，硕士

1996/08-1999/07，第四军医大学流行病学，硕士

1989/09-1994/07，同济医科大学预防医学，学士

工作经历

2022/05–至今，   南方科技大学公共卫生及应急管理学院，教授、研究员、博士生导师

2019/09-2022/04，美国德克萨斯大学MD安德森肿瘤研究中心肿瘤外科系，副教授

2012/10-2019/08，美国德克萨斯大学MD安德森肿瘤研究中心肿瘤外科系，助理教授

2011/09-2012/09，美国德克萨斯大学MD安德森肿瘤研究中心遗传学系，讲师

2009/01-2011/08,  美国德克萨斯大学MD安德森肿瘤研究中心，博士后

1999/08-2002/12，军事医学科学院微生物流行病研究所，助理研究员

1994/08-1996/07，中国学校卫生杂志社，编辑

科研项目

1. 美国国立卫生研究院，“Integration of Clinical and Molecular Biomarkers for Melanoma Survival”。

2. 安德森研究中心研究项目，“The skin microbiome and cutaneous melanoma”。

3. 国家自然科学基金面上项目，“结直肠癌肿瘤微环境免疫细胞浸润标志物及其对患者预后生存的影响”。

4. 国家自然科学基金面上项目，“应用第二代测序和生物信息学技术研究肠道微生物群系与大肠癌发病之间的关系”。

5. 美国国立卫生研究院，“Genetic polymorphisms of IL‐12p35 and IL‐23p19 in melanoma progression”。

6. 美国国立卫生研究院职业发展项目，“C-reactive protein and melanoma outcomes”。

7. 美国国立卫生研究院，“Genetic determinants of Breslow tumor thickness and their impact on melanoma progression”。

8. 美国国立卫生研究院，“Cancer Center Support Grant – Melanoma Program”。

9. 美国国立卫生研究院,  “UT M. D. Anderson Cancer Center SPORE in Melanoma-CoreA”。

代表性论文（#共同一作，*通讯作者）

1.      Wang Y#, Ramachandran V, Sui D, Xu K, Haydu LE, Fang S, McQuade JL, Fisher SB, Lucci A, Keung EZ, Wargo J, Gershenwald JE, Ross MI, Lee JE*.  Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. J Invest Dermatol. 2021 Dec 21:S0022-202X(21)02627-0. doi: 10.1016/j.jid.2021.12.012. (SCI IF = 7.14)

2.      Liu W#, Zhang R, Shu R, Yu J, Li H, Long H, Jin S, Li S, Hu Q, Yao F, Zhou C, Huang Q, Hu X, Chen M, Hu W, Wang Q*, Fang S*, Wu Q*. Study of the Relationship between Microbiome and Colorectal Cancer Susceptibility Using 16SrRNA Sequencing. BioMed Research International 2020:7828392,2020(SCI IF = 2.276)

3.      Fang S#, Hu Z, Xu T, Zhang K, Li S, Xiong M*. Mass testing and containment of Covid-19. J Emerg Med Truma Surg Care. S1:001. 6/2020. (SCI IF = 0.76)

4.      Ge Q#, Huang X, Fang S, Guo S, Liu Y, Lin W, Xiong M*. (2020). Conditional Generative Adversarial Networks for Individualized Treatment Effect Estimation and Treatment Selection. Frontiers in genetics, (2020): 585804. (SCI IF = 4.15)

5.      Feng R#, Wang Y#, Ramachandran V, Ma Q, May M, Li M, Zhou J, Xu X, Xu K, Fang S, Xia W, Sui D, Liu H, Gao X, Prieto V, Blacklow S, Lu M*, Lee J*. (2020). Characterization of novel neutralizing mouse monoclonal antibody JM1-24-3 developed against MUC18 in metastatic melanoma. Journal of experimental & clinical cancer research : CR, no. 1 (2020): 273. (SCI IF = 7.038)

6.      Fang S*#, Lu J, Zhou X, Wang Y, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Sui D, Amos CI, Lee JE*. Functional annotation of melanoma risk loci identifies novel susceptibility genes. Carcinogenesis. 2020 Jun 17;41(4):452-457. doi: 10.1093/carcin/bgz173. (SCI IF = 3.92)

7.      Fang S#*, Xu T, Xiong M, Zhou X, Wang Y, Haydu LE, Ross MI, Gershenwald JE, Prieto VG, Cormier JN, Wargo J, Sui D, Wei Q, Amos CI, Lee JE*. Role of immune response, inflammation and tumor immune response–related cytokines/chemokines in melanoma progression. J Invest Dermatol. 2019 Jun 7. doi: 10.1016/j.jid.2019.03.1158. (SCI IF = 7.14)

8.      Fang S #*, Wang Y, Dang Y, Gagel A, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Haydu LE, Davies MA, McQuade JL, Sui D, Bassett RL Reveille JD, Wei Q, Amos CI, Lee JE*. Association between body mass index, C-reactive protein levels and melanoma patient outcome. J Invest Dermatol. doi: 10.1016/j.jid.2017.04.007. (SCI IF = 7.14)

9.      Fang S#, Sui D, Wang Y, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Gardner JM, Reveille JD, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE*. Association of vitamin D levels with melanoma patient outcome after adjustment for C-reactive protein. Journal of Clinical Oncology. 2016 May 20:1741-1747. PMID: 27001565 (SCI IF = 32.96)

10.    Fang S#, Wang Y, Sui D, Liu H, Ross MI, Gershenwald JE, Cormier JM, Royal RE, Lucci A, Schacherer CW, Gardner JM, Reveille JD, Bassett Jr. RL, Wang L, Wei Q, Amos CI, Lee JE*. C-reactive protein as a marker of melanoma progression. Journal of Clinical Oncology 2015 Apr 20;33(12):1389-96. Epub 2015 Mar 16. PMID: 25779565 (SCI IF = 32.96).

11.    Fang S#, Wang Y, Amos CI, Lee JE*. Reply to Z. Li et al. Journal of Clinical Oncology e-Pub 8/2015. (SCI IF = 32.96)

12.    Fang S #*, Vaysse A#, Brossard M, Wang Y, Deng D, Liu Q, Zhang P, Xu K, Li M, Feng R, Liu H, Dang Y, Chen W, Prieto V, Gershenwald JE, Ross MI, Matejka B, Malke J, Haydu LE, Reveille JD, Sui D, Bassett RL, Koshkina N, Avril MF, Lu M, Wei Q, Demenais F, Amos CI, Lee JE*. Melanoma expression genes identified through genome-wide association study of Breslow tumor thickness. J Invest Dermatol. e-Pub 8/ 2016. PMID: 27506587. (SCI IF = 7.14)

13.    Fang S*, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JM, Royal RE, Lucci A, Schacherer CW, Reveille JD, Chen W, Sui D, Bassett RL, Wang L-E, Wei Q, Amos CI, Lee JE*. Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. J Invest Dermatol. 2015 Sep;135(9):2266-2272 (SCI IF = 7.14)

14.    Fang S #*, Wang Y, Lu M, Dang Y, Li M,Koshkina N, Feng R, Liu H, Xu K, Sui D, Wei Q, Amos CI, Lee JE*. Association of Inflammation-related Genetic Variants with Melanoma Development. Journal of Experimental Dermatology and Research 1(3):012, 5/ 2015 (Invited article).

15.    Fang S #, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Gardner JM, Schacherer CW, Reveille JD, Chen W, Sui D, Bassett Jr. RL, Wang L, Wei Q, Amos CI, Lee JE*. The relationship between blood IL-12p40 level and melanoma progression. Int J Cancer. 2014. doi: 10.1002/ijc.29182. (SCI IF = 5.14)

16.    Fang S#, Krahe R, Bachinski LL, Zhang B, Amos CI*, Strong LC*. Sex-specific effect of TP53 PIN3 polymorphism on tumor risk in a cohort study of TP53 germline mutation carriers. Human Genetic. 2011 Dec;130(6):789-94. Epub 2011 Jun 19. (SCI IF = 3.54)

17.    Fang S#, Fang X, Xiong M*. Psoriasis prediction from genome-wide SNP profiles. BMC dermatology. 2011 Jan 7; 11(1)1. (SCI IF = 1.70)

18.    Fang S#, Pinney SM, Bailey-Wilson JE, de Andrade MA, Li Y, Kupert E, You M, Schwartz AG, Yang P, Anderson MW, Amos CI*. Ordered subset analysis identifies loci influencing lung cancer risk on chromosomes 6q and 12q. Cancer Epidemiol Biomarkers Prev. 2010;19(12):3157-66. (SCI IF = 4.55)

19.    Fang S#, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI*. Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations. PLoS One 2010 5(5): e10813. doi:10.1371/journal.pone.0010813. (SCI IF = 2.77)

20.    Fang S#, Han J, Zhang M, Wang LE, Wei Q, Amos CI, Lee JE*. Joint effect of multiple common SNPs predicts melanoma susceptibility. PLoS One. 2013 Dec 31;8(12):e85642. doi: 10.1371/journal.pone.0085642. eCollection 2013. (SCI IF = 2.77)

21.    Brossard M #, Fang S#, Vaysse A, Wei Q, Chen WV, Mohamdi H, Maubec E, Lavielle N, Galan P, Lathrop M, Avril MF, Lee JE, Amos CI#, Demenais F*. Integrated pathway and epistasis analysis reveals interactive effect of genetic variants at TERF1 and AFAP1L2 loci on melanoma risk. Int J Cancer. e-Pub 4/2015. (SCI IF = 5.14)

22.    Vaysse A#, Fang S#, Brossard M#, Wei Q, Chen WV, Mohamdi H, Vincent-Fetita L, Margaritte-Jeannin P, Lavielle N, Maubec E, Lathrop M, Avril MF, Amos CI, Lee JE*, Demenais F*. A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between CDC42 and SCIN genetic variants. Int J Cancer 139(9):2012-20, 11/2016. e-Pub 7/2016. PMID: 27347659. (SCI IF = 5.14)

23.    Landi MT#*, Bishop DT, MacGregor S, Machiela MJ, Stratigos AJ, Ghiorzo P, Brossard M, Calista D, Choi J, Fargnoli MC, Zhang T, Rodolfo M, Trower AJ, Menin C, Martinez J, Hadjisavvas A, Song L, Stefanaki I, Scolyer R, Yang R, Goldstein AM, Potrony M, Kypreou KP, Pastorino L, Queirolo P, Pellegrini C, Cattaneo L, Zawistowski M, Gimenez-Xavier P, Rodriguez A, Elefanti L, Manoukian S, Rivoltini L, Smith BH, Loizidou MA, Del Regno L, Massi D, Mandala M, Khosrotehrani K, Akslen LA, Amos CI, Andresen PA, Avril MF, Azizi E, Soyer HP, Bataille V, Dalmasso B, Bowdler LM, Burdon KP, Chen WV, Codd V, Craig JE, Debniak T, Falchi M, Fang S, Friedman E, Simi S, Galan P, Garcia-Casado Z, Gillanders EM, Gordon S, Green A, Gruis NA, Hansson J, Harland M, Harris J, Helsing P, Henders A, Hocevar M, Höiom V, Hunter D, Ingvar C, Kumar R, Lang J, Lathrop GM, Lee JE, Li X, Lubinski J, Mackie RM, Malt M, Malvehy J, McAloney K, Mohamdi H, Molven A, Moses EK, Neale RE, Novakovic S, Nyholt DR, Olsson H, Orr N, Fritsche LG, Puig-Butille JA, Qureshi AA, Radford-Smith GL, Randerson-Moor J, Requena C, Rowe C, Samani NJ, Sanna M, Schadendorf D, Schulze HJ, Simms LA, Smithers M, Song F, Swerdlow AJ, van der Stoep N, Kukutsch NA, Visconti A, Wallace L, Ward SV, Wheeler L, Sturm RA, Hutchinson A, Jones K, Malasky M, Vogt A, Zhou W, Pooley KA, Elder DE, Han J, Hicks B, Hayward NK, Kanetsky PA, Brummett C, Montgomery GW, Olsen CM, Hayward C, Dunning AM, Martin NG, Evangelou E, Mann GJ, Long G, Pharoah PDP, Easton DF, Barrett JH, Cust AE, Abecasis G, Duffy DL, Whiteman DC, Gogas H, De Nicolo A, Tucker MA, Newton-Bishop JA, GenoMEL Consortium, Q-MEGA and QTWIN Investigators, ATHENS Melanoma Study Group, 23andMe, SDH Study Group, IBD Investigators, Essen-Heidelberg Investigators, AMFS Investigators, MelaNostrum Consortium, Peris K, Chanock SJ, Demenais F, Brown KM, Puig S, Nagore E, Shi J, Iles MM, Law MH*. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nat Genet 52(5):494-504, 5/2020. e-Pub 4/2020. PMCID: PMC7255059. (SCI IF = 21.11)

24.    McQuade JL#*, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee D-Y, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob J-J, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA*: The association of BMI and outcomes in metastatic melanoma: A retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy. The Lancet Oncology.2018;19:310-322. (SCI IF = 33.80)

25.    Liu S#, Wang Y, Wu W, Zhu D, Amos CI, Fang S, Lee JE, Han J, Wei Q*. Genetic Variants in the Genes Encoding Rho GTPases and Related Regulators Predict Cutaneous Melanoma-specific Survival. Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30785.

26.    Srokowski TP#, Fang S, Hortobagyi GN, Giordano SH*. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol. 2009 May 1;27(13):2170-6. Epub 2009 Mar 23. (SCI IF = 32.96)

27.    Patt DA#, Duan Z, Fang S, Hortobagyi GN, Giordano SH*. Acute Myeloid Leukemia After Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk.  J. Clin. Oncol., 2007; 25(25): 3871 – 3876. (SCI IF = 32.96)

28.    Du XL#*, Lairson DR, Begley CE, Fang S . Temporal and Geographic Variation in the Use of Hematopoietic Growth Factors in Older Women Receiving Breast Cancer Chemotherapy: Findings From Large Population-Based Cohort. J. Clin. Oncol., 2005, 23(34): 8620-8628. (SCI IF = 32.96)

29.    Badgwell BD#, Giordano SH, Duan Z, Fang S , Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, and Babiera G*. Mammography Before Diagnosis Among Women Age 80 Years and Older With Breast Cancer. J Clin Oncol;2008,26(15): 2482–2488. (SCI IF = 32.96)

30.    Chavez- MacGregor M#, Zhao H, Kroll M, Fang S ,Zhang N, Hortobagyi GN, Buchholz TA, Shih T, Giordano SH*. Risk factors and incidence of TEE in older men and women with breast cancer. Annals of Oncology. 2011 Mar 10: mdq777v1-mdq777. (SCI IF = 18.27)

31.    Telomeres Mendelian Randomization Collaboration#, Haycock PC, Burgess S, Nounu A, Zheng J, Okoli GN, Bowden J, Wade KH, Timpson NJ, Evans DM, Willeit P, Aviv A, Gaunt TR, Hemani G, Mangino M, Ellis HP, Kurian KM, Pooley KA, Eeles RA, Lee JE, Fang S , Chen WV, Law MH, Bowdler LM, Iles MM, Yang Q, Worrall BB, Markus HS, Hung RJ, Amos CI, Spurdle AB, Thompson DJ, O'Mara TA, Wolpin B, Amundadottir L, Stolzenberg-Solomon R, Trichopoulou A, Onland-Moret NC, Lund E, Duell EJ, Canzian F, Severi G, Overvad K, Gunter MJ, Tumino R, Svenson U, van Rij A, Baas AF, Bown MJ, Samani NJ, van t'Hof FN, Tromp G, Jones GT, Kuivaniemi H, Elmore JR, Johansson M, Mckay J, Scelo G, Carreras-Torres R, Gaborieau V, Brennan P, Bracci PM, Neale RE, Olson SH, Gallinger S, Li D, Petersen GM, Risch HA, Klein AP, Han J, Abnet CC, Freedman ND, Taylor PR, Maris JM, Aben KK, Kiemeney LA, Vermeulen SH, Wiencke JK, Walsh KM, Wrensch M, Rice T, Turnbull C, Litchfield K, Paternoster L, Standl M, Abecasis GR, SanGiovanni JP, Li Y, Mijatovic V, Sapkota Y, Low SK, Zondervan KT, Montgomery GW, Nyholt DR, van Heel DA, Hunt K, Arking DE, Ashar FN, Sotoodehnia N, Woo D, Rosand J, Comeau ME, Brown WM, Silverman EK, Hokanson JE, Cho MH, Hui J, Ferreira MA, Thompson PJ, Morrison AC, Felix JF, Smith NL, Christiano AM, Petukhova L, Betz RC, Fan X, Zhang X, Zhu C, Langefeld CD, Thompson SD, Wang F, Lin X, Schwartz DA, Fingerlin T, Rotter JI, Cotch MF, Jensen RA, Munz M, Dommisch H, Schaefer AS, Han F, Ollila HM, Hillary RP, Albagha O, Ralston SH, Zeng C, Zheng W, Shu XO, Reis A, Uebe S, Hüffmeier U, Kawamura Y, Otowa T, Sasaki T, Hibberd ML, Davila S, Xie G, Siminovitch K, Bei JX, Zeng YX, Försti A, Chen B, Landi S, Franke A, Fischer A, Ellinghaus D, Flores C, Noth I, Ma SF, Foo JN, Liu J, Kim JW, Cox DG, Delattre O, Mirabeau O, Skibola CF, Tang CS, Garcia-Barcelo M, Chang KP, Su WH, Chang YS, Martin NG, Gordon S, Wade TD, Lee C, Kubo M, Cha PC, Nakamura Y, Levy D, Kimura M, Hwang SJ, Hunt S, Spector T, Soranzo N, Manichaikul AW, Barr RG, Kahali B, Speliotes E, Yerges-Armstrong LM, Cheng CY, Jonas JB, Wong TY, Fogh I, Lin K, Powell JF, Rice K, Relton CL, Martin RM, Davey Smith G. Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. JAMA Oncol. 2017 May 1;3(5):636-651. doi: 10.1001/jamaoncol.2016.5945. (SCI IF = 24.80)

32.    Law MH#*, Bishop DT, Lee JE, Brossard M, Martin NG, Moses EK, Song F, Barrett JH, Kumar R, Easton DF, Pharoah PD, Swerdlow AJ, Kypreou KP, Taylor JC, Harland M, Randerson-Moor J, Akslen LA, Andresen PA, Avril MF, Azizi E, Scarrà GB, Brown KM, D?bniak T, Duffy DL, Elder DE, Fang S, Friedman E, Galan P, Ghiorzo P, Gillanders EM, Goldstein AM, Gruis NA, Hansson J, Helsing P, Hocevar M, Höiom V, Ingvar C, Kanetsky PA, Chen WV, GenoMEL Consortium, Essen-Heidelberg Investigators, SDH Study Group, Q-MEGA and QTWIN Investigators, AMFS Investigators, ATHENS Melanoma Study Group, Landi MT, Lang J, Lathrop GM, Lubinski J, Mackie RM, Mann GJ, Molven A, Montgomery GW, Novakovic S, Olsson H, Puig S, Puig-Butille JA, Qureshi AA, Radford-Smith GL, van der Stoep N, van Doorn R, Whiteman DC, Craig JE, Schadendorf D, Simms LA, Burdon KP, Nyholt DR, Pooley KA, Orr N, Stratigos AJ, Cust AE, Ward SV, Hayward NK, Han J, Schulze HJ, Dunning AM, Bishop JA, Demenais F, Amos CI, MacGregor S, Iles MM*. Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nat Genet. e-Pub 8/2015. (SCI IF = 21.11)

33.    Iles MM#*, Law MH, Stacey SN, Han J, Fang S, Pfeiffer R, et al.. A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet. 2013 Apr;45(4):428-32, 432e1. doi: 10.1038/ng.2571. Epub 2013 Mar 3. (SCI IF = 21.11)

34.    Amos CI#*, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, Kosoy R, Zhang M, Qureshi AA, Vattathil S. et al 2011. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Human Molecular Genetics. 2011 Dec 15; 20(24):5012-23. Epub 2011 Sep 17. (SCI IF = 5.10)

35.    Xiao F#, Ma J, Cai G, Fang S, Lee JE, Wei Q, Amos CI*. Natural and orthogonal model for estimating gene-gene interactions applied to cutaneous melanoma. Hum Genet. 2014 May;133(5):559-74. doi: 10.1007/s00439-013-1392-2. Epub 2013 Nov 17.

36.    Giordano SH#, Fang S, Duan Z, Kuo Y, Hortobagyi GN, and Goodwin JS*. Use of Intravenous Bisphosphonates in Older Women with Breast Cancer. Oncologist. 2008; 13: 494 - 502.

37.    Yang L#, Lu X, Deng J, Zhou Y, Huang D, Qiu F, Yang X, Yang R, Fang W, Ran P, Zhong N, Zhou Y, Fang S, Lu J*. Risk factors shared by COPD and lung cancer and mediation effect of COPD: two center case-control studies. Cancer Causes Control. 2015 Jan;26(1):11-24. doi: 10.1007/s10552-014-0475-2. Epub 2014 Dec 7.

38.    Song F#, Amos CI, Lee JE, Lian CG, Fang S, Liu H, MacGregor S, Iles MM, Lindeman NI, Montgomery GW, Duffy DL, Cust AE, Jenkins MA, Whiteman DC, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Brown KM, Martin NG, Mann GJ, Bishop DT, Newton Bishop JA, the GenoMEL consortium, Kraft P, Qureshi AA, Kanetsky PA, Hayward NK, Hunter DJ, Wei Q, Han J*. Identification of a melanoma susceptibility locus and somatic mutation in TET2. Carcinogenesis. e-Pub 6/2014.

39.    Park JY#, Amankwah EK, Anic GM, Lin HY, Walls B, Park H, Krebs K, Madden M, Maddox K, Marzban S, Fang S, Chen W, Lee JE, Wei Q, Amos CI, Messina JL, Sondak VK, Sellers TA, Egan KM*. Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression. Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):827-34. doi: 10.1158/1055-9965.EPI-12-1129. Epub 2013 Mar 5.

40.    Zhang W#, Liu H, Liu Z, Zhu D, Amos CI, Fang S, Lee JE, Wei Q*. Functional Variants in Notch Pathway Genes NCOR2, NCSTN, and MAML2 Predict Survival of Patients with Cutaneous Melanoma. Cancer Epidemiol Biomarkers Prev. e-Pub 5/2015.

41.    Gorlov IP#*, Logothetis CJ, Fang S, Gorlova OY, Amos CI. Building a Statistical Model for Predicting Cancer Genes. PLOS One 7(11):e49175, doi:10.1371/journal.pone.0049175, 2012.

42.    Du XL#*, Fang S, Coker AL, Sanderson M, Aragaki C, Cormier JN, Xing Y, Gor BJ, Chan W. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma. Cancer 2006,106(6):1276-1285.

43.    Srokowski TP#, Fang S, Duan Z, Buchholz TA, Hortobagyi GN, Goodwin JS, Giordano SH. Completion of adjuvant radiation therapy among women with breast cancer. Cancer. 2008 Jul 1;113(1):22-9. Erratum in: Cancer. 2008 Nov 1;113(9):2615

44.    Du XL#*, Fang S, Meyer TE. Impact of Treatment and Socioeconomic Status on Racial Disparities in Survival among Older Women with Breast Cancer. American Journal of Clinical Oncology. 2008;31(2):125-132.

45.    方沈应,李远贵,苏景宽,徐德忠, 部队人群甲肝疫苗接种的成本-效益分析. 解放军预防医学杂志, 2000,18(4):251-253.

46.    方沈应. 部队人群乙肝疫苗接种决策分析. 解放军预防医学杂志, 1999,17(2):153-156.

47.    张治英,高红丽,徐德忠,李远贵,苏景宽, 方沈应, 部队甲型病毒性肝炎疫苗的接种策略. 第四军医大学学报, 2000年21卷10期